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ABSTRACT 
It is known that some survivors of childhood, adolescent and young adult cancer are at increased risk 
of gonadal dysfunction and adverse pregnancy outcomes. We reviewed currently available literature 
evaluating reproductive function and pregnancy outcomes of female cancer survivors diagnosed 
before the age of 25. High dose alkylating agent chemotherapy and abdominal/pelvic radiotherapy 
adversely impact gonadal function in a dose-related fashion, with older age at exposure conferring 
greater risk due to the age-related decline in ovarian reserve. Gonadal injury clinically manifests as 
ovarian hormone insufficiency (delayed or arrested puberty, premature ovarian insufficiency, or 
premature menopause) and infertility. The effect of molecular-targeted agents on ovarian function 
has not been established. For female survivors who maintain fertility, overall pregnancy (relative risk 
0.67-0.81) and live birth rates (hazard ratio 0.79-0.82) are lower than those in the general public. 
Pregnancy in survivors of cancer may also be associated with risks to both the mother and fetus, 
related to miscarriage, preterm birth, and, rarely, cardiomyopathy. Women at risk for these 
complications require pre-conception assessment and counseling by both obstetricians and oncology 
providers. The risk for inherited genetic disease in offspring conceived after cancer treatment 
exposure is not increased. Optimizing reproductive outcomes and minimizing risks of pregnancy 
complications in survivors requires informed risk-based assessment and monitoring. 
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Introduction 
The childhood cancer survivor population has been growing rapidly over the last four decades with 
five-year survival rates now approximately 80% in the developed world. Despite increasing survival, 
the majority of these survivors will experience at least one and often several chronic health 
conditions by age 40 years that will significantly impact on their overall quality of life
1,2
. Among the 
health consequences of cancer, gonadal dysfunction and infertility are major concerns of survivors 
and their parents, resulting in distress, fear, anxiety and interference with intimate relationships
3
. 
Identifying risk factors that impact on reproductive function and fertility is important to facilitate 
accurate counseling and timely referral for established (e.g. oocyte and embryo cryopreservation) 
and experimental (e.g. ovarian tissue cryopreservation) interventions that may help to restore future 
fertility in high-risk populations (reviewed elsewhere
4
).  In this review, we assess currently available 
literature evaluating reproductive function and pregnancy outcomes of female childhood, adolescent 
and young adult cancer survivors diagnosed before the age of 25. 
 
Cancer therapy and gonadal function 
It is well established that some survivors are at increased risk of damage to reproductive function, 
which may manifest as ovarian hormone insufficiency (absent or arrested puberty, premature 
ovarian insufficiency (POI), also referred to as early menopause) and infertility
4
. POI was defined as a 
clinical condition that developed in any adult female at age < 40 years, characterized by the absence 
of menstrual cycles for ≥ 4 months and two elevated serum follicle-stimulating hormone levels in the 
menopausal range
5
. Compared to siblings, the risk of nonsurgical POI is increased, with a cumulative 
incidence of approximately 8-10% by age 40 years
6-8
. These manifestations generally reflect direct or 
indirect adverse effects of cancer treatment on the non-renewable pool of primordial follicles within 
the ovary
9
.  
 
The body of evidence describing adverse effects of multi-modal cancer therapies on female 
reproductive function is largely based on retrospective cohort studies
10
. Dissecting the contribution 
of individual therapeutic components in these studies is often difficult but increasingly data are 
available that elucidate predisposing treatments. These studies confirm that amongst 
chemotherapeutic agents, the alkylating agents impart higher risk, in a dose-related manner when 
both individual agents and combination of alkylating agents are used
11
. Importantly, there appears to 
be no consistent threshold for a safe alkylating agent dose.  
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The ovaries may also be damaged by radiation to a field that potentially exposes the ovaries (e.g., 
total body/abdominal/pelvic/spinal irradiation). The magnitude of the effect is related to the dose, 
fractionation schedule and age at the time of treatment. The oocyte is extremely sensitive to 
radiation with <2 Gray representing the estimated dose required to destroy 50% of primordial 
follicles
12
; normograms identifying the dose likely to cause POI across a range of ages have been 
produced
4
. 
 
Molecular-targeted agents such as monoclonal antibodies and kinase inhibitors are increasingly used 
in the treatment of female cancer. At present, the effects of such agents on female reproductive 
function are largely unknown, but there have been reports proposing a likely transient effect of 
bevacizumab (an anti-VEGF agent) on ovarian function
13
. As follicle growth is dependent on 
angiogenesis, normal folliculogenesis may be impaired by this agent; effects on the non-growing 
ovarian follicle pool remain unknown. Other agents may have effects on the non-growing primordial 
follicle pool through activity on pathways of physiological relevance to the control of follicle 
dormancy and growth activation. One potential example of this is imatinib, which has been reported 
to have adverse effects on ovarian function
14
 but may also have protective effects against the 
gonadotoxicity of cisplatin
15
. The effect of 131I-metaiodobenzylguanidine for neuroblastoma is 
unclear, since only two cases have been reported resulting in damage to the female gonads, but 
because of the localisation of the tumours (pelvis) the ovaries might have received some scattered 
irradiation
16
. 
 
Diagnosing Premature Ovarian Insufficiency 
POI, in addition to compromising fertility, is associated with osteoporosis, cardiovascular diseases, 
impaired well-being and compromised sexual health
5,17
. Therefore, surveillance of at risk survivors 
may facilitate early detection and access to interventions that preserve health and improve quality of 
life
18,19
.   
Several initiatives have developed national guidelines for POI surveillance in survivors
20-23
. However, 
many differences were observed, resulting in difficulties in implementing guidelines in clinical 
practice. As part of a larger international effort to harmonize existing late effects screening 
recommendations for survivors of childhood cancer, POI surveillance recommendations for female 
survivors were reviewed
19
. In Figure 1, the harmonized recommendations are shown. Gaps in 
knowledge were also identified, including  the lack of information on safe treatment dosages and the 
role of genetic susceptibility on subsequent POI risk, to lead future directions in research. 
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Assessment for POI should begin, as appropriate for age, with documentation of pubertal, menstrual 
and pregnancy history and symptoms (e.g. hot flashes) and physical findings of ovarian hormone 
insufficiency (e.g. delayed/stalled puberty). Amongst useful biomarkers, FSH remains the key 
hormone of diagnostic value for POI but there are now increasing data on the value of AMH in 
identifying those women with low ovarian reserve following cancer therapy
24
. The value of AMH in 
predicting early menopause remains uncertain, and it is also important to recognise that a very low 
AMH does not preclude natural conception. Thus while this biomarker is of great value in a research 
context, its value in routine clinical practice is less clear. Antral follicle count by transvaginal 
ultrasound is also an established method for assessing ovarian reserve in adult women, but is not 
part of the definition of POI. 
 
Treatment of ovarian hormone insufficiency 
Sex steroid replacement therapy (SSRT) can remediate or prevent the consequences of estrogen 
deprivation in survivors with POI. SSRT differs for survivors who are pre-pubertal and those who 
experience POI after secondary sexual characteristics have developed. Timing and tempo of estrogen 
substitution in the pre-pubertal patient are crucial to ensure normal pubertal development 
(especially breast development) and an acceptable final height and ideally should be managed by a 
provider with expertise in paediatric pubertal development. In post-pubertal females, SSRT promotes 
bone and cardiovascular health
25
. Progesterone therapy is also needed to avoid endometrial 
hyperplasia and cancer in women with a uterus once breast development is complete.  
In non-cancer survivors, POI is treated with SSRT to remediate symptoms of low estrogen. Moreover, 
women should be advised that SSRT may have a role in primary prevention of diseases of the 
cardiovascular system and for bone protection
5
. In these women, SSRT use before the age at natural 
menopause has not been found to increase the risk of breast cancer
5
. Unfortunately, literature on 
the effects of SSRT in female cancer survivors is scarce. Similarly there are limited data on oral versus 
transdermal administration. A crossover study of oral versus transdermal SSRT in young women with 
POI related to Turner syndrome and childhood cancer treatment showed that transdermal treatment 
is more effective than standard oral treatment in terms of bone health and cardiovascular health 
26-
28
. Numbers are limited and study groups heterogeneous, which emphasizes the importance of 
pursuing randomized studies evaluating SSRT in survivors.  
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While most providers would uniformly recommend SSRT to support pubertal development and 
growth, use of SSRT in older patients is variable, in part due to concerns about induction of second 
malignant neoplasms, especially breast cancer. In this regard, recent research from the Childhood 
Cancer Survivor Study reported that survivors with POI treated with SSRT have a lower risk of breast 
cancer compared to those who continue to menstruate naturally. These data suggest that SSRT does 
not affect breast cancer risk to same degree as endogenous hormones
29
. 
 
Pregnancy Rates 
For survivors of reproductive-age, concerns about achieving pregnancy, maternal health during 
pregnancy and pregnancy outcomes represent priority health concerns. Large cohort studies have 
demonstrated that overall, female cancer survivors have lower rates of pregnancy
30-32
 and live 
births
32-35
 compared to sibling and general population controls (see Table 1). Risks for lowest rates 
occur following exposure to cranial and abdominal radiation. Abdominal radiotherapy is also 
associated with delayed time to pregnancy
36
 and in a large German cohort of Hodgkin lymphoma 
survivors, pelvic radiotherapy was the key determinant of not achieving parenthood
37
. Pelvic 
radiotherapy may also affect the uterus with consequences for early and late pregnancy loss, and 
pregnancy complications (discussed below). 
 
Chow et al demonstrated that survivors who received chemotherapy alone had lower live birth rates 
with HR 0.82 (confidence interval 0.76 to 0.89)
32
. Cyclophosphamide equivalent dose was associated 
at the highest doses with lower live birth rates (upper quartile vs no exposure: HR 0.85, confidence 
interval 0.74-0.98). Detailed information on treatment revealed that only busulfan and lomustine 
were identified as specific agents associated with reduced chance of pregnancy. This study also 
highlighted the impact of delaying pregnancy such that the effect of chemotherapy was magnified in 
women whose first pregnancy was after 30 years of age; thus there seems to be some evidence of 
age-related loss of fertility. This has clear implications for advising young women about the timing of 
pregnancy after cancer treatment. Higher pregnancy rates have been reported in more recent 
treatment eras, likely reflecting risk-adapted use of gonadotoxic treatment modalities
35
. 
 
It is important to note that pregnancy rates are not synonymous with either fertility or infertility. In 
the former, factors other than treatment exposure can affect pregnancy such as having a partner and 
the desire for having children. In addition, the presence of clinical infertility does not necessarily 
preclude pregnancy, especially with the use of assisted reproduction
36
. 
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Pregnancy Outcomes 
As in the general population, live birth rates in survivors are lower than pregnancy rates reflecting 
losses during pregnancy
32
. Cohort and national registry data show that spontaneous pregnancy loss 
<22 weeks of gestation occurs with limited frequency (7-15%) in survivors, comparable in rate to 
sibling and population controls
38-40
. However higher spontaneous pregnancy loss rates have been 
reported in women exposed to cranial radiation (1.4- to 6.1-fold increase) and abdomino-pelvic 
radiation (1.4- to 2.8-fold increase)
33,38,39
. Of particular concern is the observation that second-
trimester losses are significantly increased in women with these exposures
33,39
. Abdomino-pelvic 
radiation is hypothesized to damage the endometrium, myometrium, or uterine vessels
41-43
. 
Preterm birth <37 weeks gestation poses significant risks to offspring and occurs in 13-21% of 
pregnancies in survivors
44,45
. Compared to siblings or the general population, these rates are 1.5- to 
2-fold higher in survivors, including similarly elevated relative risks for early preterm births prior to 
32 weeks
44-47
. Preterm birth risk is related to  abdomino-pelvic radiation in a dose-dependent 
fashion, but does not appear to vary by radiation before or after menarche
33,39,44
. Most data report 
no association between preterm birth and exposure to alkylating chemotherapy
33,44
. There is a 
dearth of data on risks of very early preterm birth (<28 weeks), as well as causes for preterm birth, 
i.e. spontaneous versus iatrogenic. Hence, there remains a lack of studies on how to prevent this 
adverse late effect. 
 
Concordant with higher rates of preterm birth, low birth weight babies (<2500 grams) occur in 7-15% 
of offspring of cancer survivors, which is 2- to 3-fold more frequently than in the offspring of 
controls
39,44,45,48
. With the exception of abdomino-pelvic radiation, higher rates of offspring being 
small for gestational age are not observed, suggesting that most of low birth weight risk is 
attributable to preterm birth rather than intrauterine growth restriction
44,45,49
. Overall, cancer 
survivors do not appear to be at higher risk of stillbirth when compared to the general 
population
38,47
. However, similar to other pregnancy outcomes, abdomino-pelvic radiation exposure 
may be associated with higher perinatal death risk, but studies are limited in power due to overall 
low incidence
33,50-52
. 
 
Cancer treatment exposures including anthracyclines, chest radiation, and molecular-targeted agents 
pose cardiovascular risks that can impact pregnancy outcomes. Several cohort studies report 
approximately 5% absolute risk of pre-eclampsia during pregnancy in cancer survivors, but rates are 
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not higher or only modestly (1.4-fold) higher than in controls
45,53,54
. In the British Childhood Cancer 
Survivor Study, survivors of Wilms tumor treated with abdominal radiotherapy were at a threefold 
risk for the development of hypertension during pregnancy. Pregnancy-associated cardiomyopathy 
occurred rarely (0.3%) in a retrospective cohort study of 847 survivors, but increased risk was 
observed with anthracycline exposure
55
. Hence, the International Late Effects of Childhood Cancer 
Guideline Harmonization Group recommends that cardiomyopathy surveillance is reasonable before 
pregnancy or in the first trimester for all female survivors treated with anthracyclines or chest 
radiation
56
. With increased use of targeted therapy, long-term and pregnancy-related cardiotoxicity 
of these agents requires further study. 
During pregnancy, overall rates of gestational diabetes are low (<5%) and are not consistently higher 
in cancer survivors than controls
45,54
. However, abdominal radiation has been associated with a 2.7 to 
4.7-fold higher risk in one study
33
. Cesarean deliveries are consistently 1.2 to 2.3-fold higher in 
survivors than controls
45,54
.  
 
Because of these potential pregnancy-related complications, survivors would benefit from 
preconception counseling to estimate magnitude of risk, establish a surveillance plan, and discuss 
interventions to reduce risk; obstetricians and oncology providers need to be aware of these 
complications to co-manage survivors accordingly (see Figure 2). There is a dearth of intervention 
studies focused on improving these adverse perinatal outcomes. Moreover, these data were derived 
from cohorts treated with regimens that may no longer be in practice and may be less applicable for 
counseling patients treated with more contemporary treatment strategies. 
 
 
Health risks in offspring 
Childhood cancer survivors represent one of the largest groups of people exposed to well-
documented high doses of potent mutagens, in the form of chemotherapy and radiation therapy, 
that might affect human germ cells, and cause potential transmissibility of germline damage to 
offspring
57
 . Health indicators of a possible mutagenic effect of cancer therapy that have been 
considered include single gene disorders and chromosomal abnormalities (rare but purely genetic 
diseases), the relatively common congenital malformations (which, although to some extent 
genetically determined, are multifactorial) as well as miscarriage, stillbirths and perinatal death. The 
occurrence of cancer and sex ratio alterations have also been considered as appropriate measures of 
germ-cell mutations in the next generation.Although most early studies lacked sufficient statistical 
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power, their findings suggest a low risk of treatment-induced heritable genetic effects. Findings of 
more recent, larger and refined studies are shown in Table 2.  
Five population-based Nordic studies evaluating the risk of sex-ratio
58
, congenital malformations
59,60
, 
chromosomal abnormalities
61
, and hospitalizations
62
 in offspring of survivors did not observe a 
significantly increased risk. In the largest population-based study to date that evaluated cancer risk in 
the next generation, 9877 children born to survivors showed no increased risk of cancer except in the 
rare event of a familial cancer syndrome
63
.A population-based cohort study from the BCCS reporting 
on sex ratio alterations
64
 maximized the statistical power by pooling their data with those from 
previous large-scale studies
58
. The sex ratio of the offspring of survivors treated with potentially high-
dose gonadal irradiation was not significantly different from that of survivors treated with 
presumably low-dose gonadal irradiation (OR 0.92; 0.78–1.08). These findings were confirmed by 
more recent studies in the USA
45
 and Western Australia
54
. 
 
Although the design and methodology differed between the more recently published studies on the 
risk of congenital malformations in the offspring, no significantly increased risks have been 
reported
45,46,51,54,59,60
. Two comprehensive studies evaluated the risk of genetic disease in children of 
childhood cancer survivors
65,66
. Strong evidence was provided that potentially mutagenic 
chemotherapy and radiotherapy doses to the ovaries were not associated with genetic defects in the 
children. Consistent with the epidemiological studies, no evidence for an increased rate of germline 
minisatellite mutations at hypervariable loci, markers for radiation-induced human germline 
mutation, was identified in parents who had received radiotherapy
67
. 
 
To date, no environmental exposure including cancer therapy has been proven to cause human germ 
line mutations that manifest as heritable disease in the offspring
57
. It has been suggested that 
inadequate study size, but also failure to measure the appropriate outcome might explain the 
reassuring results reported in the vast majority of studies on health risks in offspring
57
. Total genomic 
sequencing directly evaluating the presence of genetic damage in germ cells and epigenomic analysis 
might be a way forward to address this issue in the future particularly in the era of targeted cancer 
therapies that include epigenetic modifiers
68
. 
 
 
Conclusion 
Over the last decades, the adverse effects of cancer and its therapy on reproductive outcomes have 
become clear, especially after specific treatment. Yet, significant gaps in knowledge continue to limit 
the ability to assess risk for gonadal failure in individual patients receiving these therapies. Little is 
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known about how host factors such as genetic risks for infertility or differences in drug metabolism 
affect risk from treatment.  The impact of newer (molecular-targeted) agents is virtually unknown. 
And, once therapy is delivered and a gonadotoxic insult has occurred, we know little about whether 
there is compensation in the rate of decline of ovarian reserve.  Furthermore, the methods by which 
we assess impending ovarian insufficiency and loss of the reproductive window still remain 
extremely inexact, limiting the ability to counsel survivors about making reproductive decisions. 
 
We recommend that all clinical trials and treatment strategies for with cancer include surveillance for 
adverse effects on reproductive health, which in female patients should include assessment of 
ovarian function, pregnancy outcomes and fertility (Figure 2). Detailed information about  
chemotherapy and radiotherapy exposures should routinely be collected to correlate with 
reproductive outcomes  as treatment exposures rather than the nature of the cancer largely 
determines risks for chronic health conditions, including gonadal function and fertility in cancer 
survivors. Survivors should receive personalized counselling about type and magnitude of 
reproductive health risks based on their specific treatment exposure and studies should be 
established to determine the efficacy of fertility preservation procedures that are undertaken in this 
population.  
 
While oncofertility options have expanded globally, there still exists a need to identify the specific 
fertility threats related to the primary cancer and  treatment patterns by country. Woodruff et al 
proposed a global oncofertility index  to permit experts to determine the scale of the problem and 
facilitate the development of  educational tools  that define access to  reproductive technologies
69
.   
As identified in the IGHG POI guideline, there are major gaps in knowledge, such as the lack of 
information about safe treatment dosages, safety of novel therapies, and the role of genetic 
susceptibility on subsequent POI risk in survivors
19
.  
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Figure 1: Harmonized recommendations for POI surveillance in survivors of childhood, 
adolescent and young adult cancer. Premature ovarian insufficiency (POI) is defined as a clinical condition developing in any adult 
female before age 40 years that is characterized by the absence of menses for >4 months and two elevated serum follicle-stimulating hormone (FSH) 
levels in the menopausal range (on the basis of the maximum threshold of the laboratory assay used). *Treatments with evidence of causing POI 
include alkylating agents in general (level A evidence), cyclophosphamide, procarbazine (level C evidence), and radiotherapy to a field that includes the 
ovaries (level A evidence). †At least annually, with increasing frequency as clinically indicated based on growth  and  pubertal  progression.  ‡At  least  
for  girls  of 11 years of age and older, and for girls with primary amenorrhoea (age 16). §If amenorrhoea, measure FSH and oestradiol randomly; if 
oligomenorrhoea, measure during early follicular phase (day  2-5).  This assessment should be performed after ending oral contraceptive pill/sex steroid 
replacement therapy use, ideally after two months without oral contraceptive pills. ¶The absence of initiation of puberty (Tanner stage 2  breast  
development)  in  girls 13 years or older or failure to progress in pubertal stage for $  12   months.   AMH, anti-Mu
¨
llerian hormone; CAYA, childhood, 
adolescent, and young adult; Level A, high level of evidence; Level B, moderate/low level of  evidence;  Level  C,  very  low  level  of evidence
19
. 
 
General recommendation 
Survivors treated with one or more potentially gonadotoxic treatments*, and their providers, 
should be aware of the risk of premature ovarian insufficiency and its implications for future 
fertility (level A and level C evidence). 
Who needs surveillance? 
Counselling regarding the risk of premature ovarian insufficiency and its implications for 
future fertility is recommended for survivors treated with: 
• Alkylating agents in general (level A evidence) 
• Cyclophosphamide and procarbazine (level C evidence) 
• Radiotherapy potentially exposing the ovaries (level A evidence) 
 
What surveillance modality should be used for pre- and peri-pubertal survivors? 
Monitoring of growth (height) and pubertal development and progression (Tanner stage) is 
recommended for pre-pubertal survivors treated with potentially gonadotoxic chemotherapy 
and/or radiotherapy potentially exposing the ovaries (expert opinion/no literature search).
*†
 
FSH and oestradiol are recommended for evaluation of premature ovarian insufficiency in 
pre-pubertal survivors treated with potentially gonadotoxic chemotherapy and/or 
radiotherapy potentially exposing the ovaries* who fail to initiate or progress through puberty 
(expert opinion/no literature search).
‡§
 
What surveillance modality should be used for post-pubertal survivors? 
A detailed history and physical examination with specific attention for premature ovarian 
insufficiency symptoms, e.g. amenorrhoea and irregular cycles is recommended for 
post-pubertal survivors treated with potentially gonadotoxic chemotherapy and/or 
radiotherapy potentially exposing the ovaries (expert opinion/no literature search).* 
FSH and oestradiol are recommended for evaluation of premature ovarian insufficiency in 
post-pubertal survivors treated with potentially gonadotoxic chemotherapy and/or 
radiotherapy potentially exposing the ovaries* who present with menstrual cycle dysfunction 
suggesting premature ovarian insufficiency or who desire assessment about potential for 
future fertility. Hormone replacement therapy should be discontinued prior to laboratory 
evaluation when applicable (expert opinion/no studies).
§||
 
AMH is not recommended as the primary surveillance modality for evaluation of premature 
ovarian insufficiency in survivors treated with potentially gonadotoxic chemotherapy and/or 
radiotherapy potentially exposing the ovaries* who desire assessment about potential future 
fertility (expert opinion/no studies). 
AMH may be reasonable in conjunction with FSH and oestradiol for identification of 
premature ovarian insufficiency in survivors treated with potentially gonadotoxic 
chemotherapy and/or radiotherapy potentially exposing the ovaries* aged ≥25 years who 
present with menstrual cycle dysfunction suggesting premature ovarian insufficiency or who 
desire assessment about potential for future fertility (expert opinion/no studies). 
When should pre- and peri-pubertal survivors be referred? 
 
Referral to paediatric endocrinology / gynaecology is recommended for any survivor who has 
• No signs of puberty by 13 years of age. 
• Primary amenorrhoea by 16 years of age. 
• Failure of pubertal progression.¶ 
(expert opinion/no literature search) 
 
When should post-pubertal survivors be referred? 
Referral to gynaecology / reproductive medicine / endocrinology (according to local referral 
pathways) is recommended for post-pubertal survivors treated with potentially gonadotoxic 
chemotherapy and/or radiotherapy potentially exposing the ovaries* who present with 
menstrual cycle dysfunction suggesting premature ovarian insufficiency (expert opinion/ 
no literature search). 
What should be done when abnormalities are identified in pre-, peri- and post-pubertal 
survivors? 
Consideration of sex steroid replacement therapy is recommended for pre-, peri- and post- 
pubertal survivors diagnosed with premature ovarian insufficiency by referral to 
gynaecology/ endocrinology (expert opinion/no literature search). 
What should be done when potential for future fertility is questioned? 
Referral to gynaecology / reproductive medicine / endocrinology (according to local referral 
pathways) is recommended for post-pubertal females treated with potentially gonadotoxic 
chemotherapy and/or ovarian irradiation* without signs and symptoms of premature ovarian 
insufficiency who desire assessment about potential for future fertility (expert opinion/no 
literature search). 
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Table 1: Pregnancy and Live Birth Rates in Childhood Cancer Survivors. 
CCSS=Childhood Cancer Survivor Study, Gy=Gray, RR=relative risk, CI=confidence interval, BCCSS=British Childhood Cancer Survivor Study, O/E=Observed/Expected, RT=radiotherapy, AIEOP=Italian Pediatric Ematology and Oncology Association, CNS=central nervous 
system, HR=hazard ratio.  
Author, year Study Cohort (n=) Treatment period Age at 
diagnosis 
Control group Pregnancy 
Rates 
Live Birth Rates Risk estimate 
Green 2009
30
 CCSS (n=5149) 1970-1986 0-21 years Sibling controls RR 0.81  
(0.73-0.90) 
Not reported Hypothalamic/pituitary radiation dose > 
or = 30 Gy (RR, 0.61; 95% CI, 0.44 to 
0.83) or an ovarian/uterine radiation 
dose greater than 5 Gy were less likely 
to have ever been pregnant 
Reulen 2009
33
 BCCSS (n=10,483) 1940-1991 0-14 years General population 
England and Wales 
Not reported O/E 0.64 (0.62-
0.66) 
Brain and abdominal RT 
Stensheim 
2011
31
 
Cancer Registry of 
Norway 
(n=16,105) 
1967-2004 16-25 years 
(subset of 
total study)  
General population HR 0.67  
(0.63-0.73) 
Not reported Not applicable as risks reported for total 
cohort (age 16-45) 
Pivetta 2011
34
 Italian AIEOP Off-
Therapy Registry 
(n=2,670) 
1960-1998 0-14 years General Population Not reported O/E 0.57 (95
th
 
0.53-0.62) 
 
Malignancy of the CNS 
Chow 2016
32
 CCSS, 
chemotherapy 
only (n=5,298) 
1970-1986 0-21 years Siblings HR 0.87  
(0.81-0.94; 
p<0.0001 
HR 0·82,  
(0·76–0·89; 
p<0·0001) 
Busulfan, higher doses of lomustine 
(≥411mg/m
2
) and cyclophosphamide 
equivalent doses in the upper quartile 
(≥11 295 mg/m
2
). 
Armuand 
2017
35
 
Swedish National 
Patient Register 
(n=552) 
Patients born 
between 1973-
1977 
0-21 years Age matched 
controls from the 
general population 
Not reported HR0.79 
before 1988 HR 
0.71 
after 1988  0.90 
Malignancy of the eye, CNS or leukemia 
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Table 2: Health risk outcomes in cancer survivor offspring
1
.  
Refe
renc
e 
Study cohort Offspring (no.), 
(CS no.) 
Outcome Comparison  Cancer (treatment) Health risk outcomes 
measures  
Risk estimate (95% CI) 
Chiar
elli 
2000
51
 
 
Female CCS -
Ontario 
Cancer 
Registry, 
diagnosis < 20 
yr (1964–
1988) 
594 singleton 
pregnancies (340 
survivors) 
Questionnai
re 
Internal comparison: 
Patients treated with 
non-sterilizing surgery 
only or no treatment 
Medical records.  
5 treatment groups: non-sterilizing 
surgery; AA; AP irradiation: low ≤ 
25 Gy, high > 25 Gy;  AA plus AP 
irradiation; and all other 
treatments 
Congenital 
malformations (22 
cases)  
-CS with AP irradiation: 
OR 0.45 (0.12-1.70) 
-General: decreased risk of 
having an infant with a 
congenital anomaly compared 
with those having surgery only 
-No effect of high dose vs low 
dose AP radiation (small no.) 
Wint
her 
2003
58
 
 
CCS - Danish 
Cancer 
Registry, 
diagnosis <20 
yr (1943–
1996) 
2130 offspring 
(born to 550 
female and 550 
male survivors)  
Registry 
linkage 
General Danish 
Population 
 
Internal comparisons 
Registry-based information on 
radiotherapy (yes/no) 
 
5 categories of estimated radiation 
dose to gonads: low/ low-
medium/ medium/ medium-high/ 
high 
Sex ratio alterations 
(2130 offspring) 
 
 
-male (0.99): female (1.00) ratio 
vs Danish population (1.06)  
-no effect of RT on  the M:F ratio  
-p for trend with ovarian dose = 
0.51  
Wint
her 
2004
61
 
CCS - Danish 
Cancer 
Registry, 
diagnosis < 20 
yr (1943–
1996) 
2630 offspring 
(4676 female and 
male survivors) 
 
 
Registry 
linkage 
Offspring of siblings  Registry-based information on RT 
(yes/no) 
 
Information on CT abstracted from 
medical records (for survivors with 
affected outcomes only) 
Chromosomal 
abnormalities 
(8 survivors with ≥1 
child/ fetus with an 
abnormal karyotype) 
Proportion of live-born children 
with abnormal karyotypes born 
to CS : 0.21% and siblings 0.21% 
Direct comparison with siblings’ 
offspring: 
Down syndrome (RR 1.07; 95% 
CI, 0.16–5.47), Turner syndrome 
(RR, 1.32; 95% CI, 0.17–7.96). 
Reul
en 
2007
64
  
BCCSS - 
National 
Registry of 
Childhood 
Tumours, 
diagnosis < 15 
6232 offspring 
(born to 3218 
female and male 
survivors) 
Questionnai
re obtained 
from general 
practitioners 
General population of 
England and Wales 
 
Internal comparisons 
among female CCS:  
Registry-based information on RT 
(yes/no) and CT (yes/no). 
 
High vs low estimated RT dose to 
gonads 
Sex ratio alterations 
(6232 offspring) 
-M:F ratio CCS offspring vs 
general population: 
1.08 (1.01-1.15) vs 1.05  
-RT only vs no RT and CT:  
OR 0.97 (0.81-1.16) 
15 
 
yr (1940–
1991) 
 -CCS without CT/RT 
-High vs low gonadal 
dose 
 
 
-CT only vs no RT and CT  
OR 1.00 (0.77-1.30) 
-High-dose vs low dose gonadal 
RT 
OR 0.95 (0.77-1.18) 
Mag
elsse
n 
2008
46
 
CS – Norway, 
diagnosis 15-
35 yr (1980–
1997) 
First-born 
offspring (number 
not stated) 
(born to 251 
female CS and 
487 male CS) 
Registry 
information 
First-born offspring in 
the general population 
of Norway 
 
 
Hospital-based information on 
cancer treatment  
4 categories: surgery alone, RT (+/-
surgery), CT (+/-surgery), and RT 
and CT (+/-surgery) (not included 
in analyses for malformation 
outcome) 
Congenital 
malformations (7 
cases) 
OR 0.7 (0.4-1.6) in female CS          
 
 
Wint
her 
2009
59
 
CCS - Danish 
Cancer 
Registry, 
diagnosis <20 
yr (1950–
1996) 
1715 offspring       
(born to 970 
survivors)  
Registry 
linkage 
Offspring of siblings  
 
-Registry-based information on on 
RT (yes/no) 
-4 categories of estimated RT dose 
to ovary and uterus: low/ low-
medium/ medium-high/ high 
Congenital 
malformations 
(44 cases at birth; 96 
cases later in life) 
Prevalence proportion ratio at 
birth, survivors’ vs siblings’ 
offspring: 1.1 (0.8–1.5) or versus 
general Danish population 
Observed-to-expected ratio, 1.2 
(0.9–1.6) 
Offspring of irradiated vs non-
irradiated parents (PPR, 1.2 vs 
1.0 at birth) 
Including malformations 
diagnosed later in life no ratio 
change 
Muel
ler 
2009
45
 
CS -  Seattle, 
Utah, Detroit 
and Atlanta, 
USA, diagnosis 
<20 yr (1973–
2000) 
1898 first live 
births (born to 
898 CS; 892 CCS; 
1006 adolescent 
cervical and 
genital CS) 
Registry 
linkage 
Comparison subjects 
selected from birth 
records 
Registry-based information on 
cancer therapy 
4 categories: CT, surgery, RT, and 
combinations 
Congenital 
malformations (10 
cases) 
 
Sex ratio alterations 
(1898 offspring) 
-RR 0.92 (0.48-1.75) 
-M:F ratio among offspring in 
the two cohorts and 
comparisons were similar, 
ranging from 0.98 to 1.02 
-CCS: RR 1.00 (0.93-1.07) 
-Adolescent cervical and genital 
CS: 
RR, 0.97 (0.90-1.03)  
-No significant increased RRs for 
malformations across groups  
Mad CS - Finnish -26331 offspring Registry -Population Registry-based information on RT Cancer (65 cases in -Offspring of CS: SIR 1.67 (1.29-
16 
 
anat-
Harj
uoja 
2010
63
 
Cancer 
Registry, 
diagnosis <35 
yr (1953–
2004) 
of 12735 survivor 
parents  
-9877 children 
born after their 
parent’s diagnosis 
(4764 female and 
5113 male CS) 
linkage expectations based on 
cancer incidence rates 
in Finland (SIR) 
-Indirect comparison 
with offspring of 
siblings  
(yes/no) 
 
children born after 
their parent’s 
diagnosis) 
2.12) 
-Offspring of CS, excluding 
hereditary cases: SIR 1.03 (0.74-
1.40) 
-Offspring of siblings: SIR, 1.07 
(0.94-1.21) 
- RT no effect on the risk (SIR, 
0.91 (0.51-1.49) 
Gree
n 
2010
70
 
National 
Wilms Tumor 
LTFUS:  
Female CCS 
(and partners 
of male CS of 
Wilms tumor) 
(<Jan 2007)  
1021 pregnancies 
of ≥ 20 weeks’ 
duration, 
including 955 
liveborn 
singletons; 677 
included in 
analyses (2369 
female CS and 
partners of 2060 
male CS of Wilms 
tumor) 
Self-
administere
d 
questionnair
e  
Internal comparison  -RT doses estimated on basis of RT 
treatment protocols, and each 
patient assigned a flank irradiation 
dose category  except for those 
who received whole-abdomen 
irradiation 
-5 dose categories in Gy 
Congenital 
malformations (44 
cases) 
p for trend with radiation dose = 
0.94 
Wint
her 
2010
62
 
CCS - Danish 
Cancer 
Registry, 
diagnosis <20 
yr (1950–
1996) 
1920 offspring 
(born to 527 
female and 539 
male CS) 
Registry 
linkage 
Offspring of siblings  
 
Population-based 
comparisons 
Registry-based information on RT 
(yes/no) 
 
4 categories of estimated RT dose 
to ovary, uterus and pituitary 
gland: low/ low-medium/ 
medium-high/ high 
 
Untoward disorders 
measured as 
hospitalization in 
childhood assuming 
that hospitalization is 
an indicator of 
multifactorial genetic 
disease  
(1053 discharge 
diagnoses in CS’ 
offspring) 
HR ratios compared to 
population comparison: 
CS’ offspring: 
HHR, 1.05 (95% CI, 0.98–1.12) 
siblings’ offspring: 
1.01 (95% CI, 0.971.05)  
HRR irradiated parents vs non-
irradiated parents based on 
population comparisons (1.1 vs 
1.0) but unrelated to estimated 
radiation dose to gonads  
A 6-fold excess risk for 
hospitalization for malignant 
tumors in the offspring of 
survivors largely explained by 
hereditary cancer syndromes 
Wint CS - Danish 472 CS ; 145 case Registry -Internal comparison: Medical records, including Genetic diseases Dose–response findings: 
17 
 
her 
2012
66
 
Cancer 
Registry, 
diagnosis 
<20yr (1943–
1996) 
CS (with affected 
child or stillbirth) 
and 372 sub-
cohort members 
(including 45 
cases) 
(1/3 of a fertility 
cohort consisting 
of  1474 CS with 
2767 pregnancies 
included in the 
above case-
cohort study)  
 
linkage Non-irradiated 
survivors (for 
association with RT 
overall and for 
association with 
ovarian and uterus and 
testicular dose) 
-Non-exposed to CT 
(for association with CT 
overall) 
detailed information on 
chemotherapy and individual 
preconception RT doses to ovaries, 
uterus and pituitary gland  
defined as 
chromosomal 
abnormalities, 
congenital 
malformations, 
stillbirths, and 
neonatal deaths (181 
presumed genetic 
diseases in offspring) 
RRs for ovarian RT dose 
categories >0 to < 0.50 Gy and ≥ 
0.50 Gy (with non-irradiated 
being reference): 
1.12 and 1.04, respectively  (p = 
0.96) 
Risk of genetic disease among 
children of CS: 
-Irradiated versus non-irradiated 
CS: RR, 1.02 (0.59-1.44; p = 0.94) 
-AA vs no AA agents in CS: RR, 
0.82 (0.53-1.28; p = 0.51) 
-An association between uterine 
dose and congenital 
malformations, stillbirths, and 
neonatal death, taken together, 
was of borderline statistical 
significance (p = 0.07) with the 
highest uterine doses associated 
with a 2.3-fold increased risk 
(ns) 
Sign
orell
o 
2012
65
  
CCSS  - 
Canada/USA, 
diagnosis <21 
yr (1970–
1986) 
4699 offspring 
(born to 1627 
female and 1128 
male CS) 
 
Self-
administere
d 
questionnair
e 
Internal comparison  
Non-irradiated CS (for 
association with RT 
dose) 
 
Non-exposed to CT (for 
association with CT) 
Medical records, including AAD 
score: 1-3 (lowest, middle and top 
tertile exposure) and individual 
preconception RT doses to the 
gonads  
Congenital anomalies 
defined as cytogenetic 
abnormalities, single-
gene defects, and 
congenital 
malformations(129 
offspring with 
congenital anomalies) 
-Dose–response findings: 
ORs for ovarian RT dose 
categories low, medium, and 
high 0.87, 0.80, 0.59 
respectively (p for trend with 
radiation dose = 0.53) 
-ORs for AAD scores categories 
lowest, middle, and top tertile 
exposure were 0.63, 1.00, and 
1.13 (p for trend with AAD score 
= 0.69) 
For congenital malformations, 
ORs for ovarian radiation dose 
categories ranged from 0.84 to 
1.14, suggesting no adverse 
effect. AAD score analysis 
showed a non-significantly 
18 
 
 
 
CCS=childhood cancer survivors, yr=years, AA=alkylating agents, AP=abdomino-pelvic, Gy=Gray, M:F=male:female, BCCSS=British Childhood Cancer Survivor Study, CS=cancer survivors, SIR=standardized incidence rates, LTFUS=long-term follow-up study, 
HR=hospitalization rate, CCSS=Childhood Cancer Survivor Study, AAD=alkylating agent dose, PR=prevalence ratio. 
1 
The following health risk outcomes measures miscarriage, stillbirth and perinatal death are evaluated in the section Pregnancy Outcomes, RT=radiotherapy, 
CT=chemotherapy. 
 
  
decreased risk for the lowest 
and non-significantly increased 
risks for the middle and top 
tertile exposure 
Hagg
ar 
2014
54
 
CS -Western 
Australia 
Cancer 
Registry, 
diagnosis 15-
39 yr (1982–
2007) 
1894 first 
completed 
pregnancies 
(1894 female CS) 
Registry 
linkage  
Population-based 
comparisons without 
cancer 
5 treatment groups:, surgery only, 
CT only, RT only, CT and RT, and all 
other types and therapy 
combinations (not included in 
analyses for malformation 
outcome) 
Congenital 
malformations (12 
cases) 
 
Sex ratio alterations 
(1894 offspring) 
RR 0.78 (0.41-1.37) 
 
M:F ratio: 
RR 1.05 (0.98-1.10) 
 
 
Sepp
anen 
2016
60
 
CS - Finnish 
Cancer 
Registry, 
diagnosis < 35 
yr (1953–
2004) 
6862 offspring; 
(born to 3929 CS; 
2197 female and 
1732 male CS) 
 
2412 CCS 
offspring, 4450 
offspring of young 
adult CS 
 
Registry 
linkage  
Offspring of siblings Registry-based information on RT 
(yes/no) 
 
Congenital 
malformations 
(220 cases)  
Prevalence ratios 
CS’ vs siblings’ offspring: 
-Any anomaly: 1.17 (0.92–1.49) 
-Lip and palate anomalies:2.09 
(1.06-4.12) 
- Any anomaly in offspring of 
retinoblastoma (3.15, 1.37-
7.23), and renal tumours ( 2.13, 
1.07-4.26)(small no.) 
-No association with RT of the 
parent (1.12, 0.86-1.45) 
19 
 
Figure 2: Assessment of the postpubertal survivor 
 
POI=premature ovarian insufficiency; AFC=antral follicle count; AMH= anti-Mu
¨
llerian hormone. 
20 
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